Abstract:Mycoplasma pneumoniae pneumonia (MPP) is a common type of pneumonia among school-aged children and adolescents. Jinzhen Oral Liquid (JZOL) and Azithromycin (AZ) are commonly used treatment options in traditional Chinese medicine (TCM) and Western medicine, respectively. There are several clinical and basic research reports on their solo effect against MPP, enabling their combined treatment to become possible. However, the mechanisms and specific pharmacodynamics of their combined therapy remain unclear. In this study, we conducted a mechanistic analysis of the combination of JZOL and AZ based on network target, elucidating their modular network regulatory mechanisms. The modular mechanisms involve four modules, including hormone response, cell differentiation and migration, signal transduction, oxygen and hypoxia response, centered by TNF signaling pathway-mediated regulation. Under the instruction of computational analysis, we conducted a randomized, double-blind, three-armed, parallel-controlled, multicenter clinical study of different doses of JZOL combined with AZ for the treatment of MPP in children. At the study endpoint, the median time to clinical recovery showed statistically significant differences, which were also observed between groups for time to complete fever remission, time to relief of cough/phlegm, effective rate of chest X-ray improvement, and rate of healing of TCM symptoms. During the treatment period, there were no statistically significant differences in the rates of adverse events, serious adverse events, or adverse reactions between the groups. Different doses of JZOL combined with AZ in the treatment of MPP in children have shown the effects of shortening the course of the disease, relieving the symptoms, and improving the prognosis. The research program composed of computational prediction and clinical trials can significantly accelerate the research and development process and identify more effective treatment with good safety, which is worthy of clinical promotion. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial The research has been registered with the China Clinical Trials Registry (registration number: ChiCTR1800019007) and has passed the ethical review of the leading unit's medical ethics committee (ethics approval number: TYLL2017[Y]020). ### Funding Statement This work was supported by the Jiangsu Provincial Department of Science and Technology-Basic Research Program Natural Science Fund - Frontier Leading Technology Basic Research Special Project "Research on the efficacy substance of traditional Chinese medicine compound based on the combination of disease and syndrome" (SBK2023050003). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The research has been registered with the China Clinical Trials Registry (registration number: ChiCTR1800019007) and has been approved by the Medical Ethics Committee of the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, which is the ethical review of the leading unit's medical ethics committee (ethics approval number: TYLL2017[Y]020). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors.

Therapeutic Effect of Zhidanhuayu Oral Solution on Drug-Resistant Mycoplasma Pneumoniae Pneumonia

New progress in etiological diagnosis and treatment of mycoplasma pneumoniae infection

Effect of azithromycin combined with ambroxol in children with Mycoplasma pneumoniae pneumonia

Multi-center study of the combination of traditional Chinese medicine and western methods treatment in the mycoplasma pneumoniae lower respiratory infection in children

Effect of Early Oral Administration of Doxycycline on Macrolide Resistance in Children with Mycoplasma Pneumoniae Pneumonia: A Retrospective Study

Macrolide-resistant Mycoplasma Pneumoniae Prevalence and Clinical Aspects in Adult Patients with Community-Acquired Pneumonia in China: a Prospective Multicenter Surveillance Study

Multicenter Clinical Observation of Infantile Feirekechuan Oral Solution for Treating Mycoplasma Pneumoniae Tracheitis and Bronchitis in Children

Epidemiological Monitoring and Antibiotic Therapies of Macrolide-Resistant Mycoplasma Pneumoniae in Chinese Patients with Community-Acquired Pneumonia: A Prospective Multicenter Surveillance Study

Role of macrolides resistance in children with refractory Mycoplasma pneumoniae pneumonia

Shuanghuanglian oral preparations combined with azithromycin for treatment of Mycoplasma pneumoniae pneumonia in Asian children: A systematic review and meta-analysis of randomized controlled trials

Analysis of the Efficacy of Erythromycin Cyclic 11,12-Carbonate Combined with Azithromycin in the Treatment of Severe Mycoplasma Pneumoniae Pneumonia in Children and its Effect on Cytokines

Huai qi huang granules for the treatment of children with mycoplasma pneumoniae pneumonia: a multicenter clinical study

Clinical Characteristics of Children with Macrolide-Resistant Mycoplasma Pneumoniae Pneumonia

Azithromycin Effectiveness in Children with Mutated Mycoplasma Pneumoniae Pneumonia

Xiao’er Xiaoji Zhike Oral Liquid Combined with Azithromycin for Mycoplasma Pneumoniae Pneumonia in Children: A Systematic Review and Meta-Analysis

Correlation between Mycoplasma pneumoniae drug resistance and clinical characteristics in bronchoalveolar lavage fluid of children with refractory Mycoplasma pneumoniae pneumonia

Significance of the determination of DNA load of drug-resistant mycoplasma pneumoniae and 23sRNA gene mutation locus in children

Proteomic and mechanistic study of Qingxuan Tongluo formula and curcumin in the treatment of Mycoplasma pneumoniae pneumonia

A study of community-acquired Mycoplasma pneumoniae in Yantai, China

Unveil the Mechanism of Jinzhen Oral Liquid Combined with Azithromycin in the Treatment of Mycoplasma Pneumoniae Pneumonia Based on Network Pharmacology and Clinical Trials

Antimicrobial susceptibility of the Mycoplasma pneumoniae strains isolated from pediatric patients